# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K212576   
B Applicant Streck, Inc   
C Proprietary and Established Names MDx-Chex for BCID2   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>PMN</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.3920 -Assayed Quality ControlMaterial For ClinicalMicrobiology Assays</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission:

To obtain a substantive equivalence determination for the MDx-Chex for BCID2.

# B Measurand:

Multi-analyte quality control materials

# C Type of Test:

MDx-Chex for BCID2 is intended for in vitro diagnostic use as an external assayed quality control material to monitor the qualitative amplification, detection, and identification steps of the laboratory nucleic acid test BioFire FilmArray Blood Culture Identification 2 (BCID2) Panel on the FilmArray 2.0 and FilmArray systems. The BioFire BCID2 Panel on the FilmArray 2.0 or FilmArray Torch system detects multiple bacterial and yeast nucleic acids and select genetic

determinants of antimicrobial resistance from positive blood cultures. Control 1 - GN: Gram negative bacteria: Acinetobacter colcoaceticus-baumannii complex, Bacteroides fragilis, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae group, Proteus spp., Salmonella spp., Serratia marcescens, Haemophilus influenza, Neisseria meningitides, Pseudomonas aeruginosa, Stenotrophomonas maltophilia; antimicrobial resistance genes: KPC, CTX-M, IMP, NDM, OXA-48-like, VIM, mcr-1. Control 2 - GPY: Gram positive bacteria: Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunesis, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes; yeast: Candida albicans, Candida auris, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans/gatti; antimicrobial resistance genes: mecA/C and MREJ, vanA/B.

# III Intended Use/Indications for Use:

# A Intended Use(s):

MDx-Chex for BCID2 is intended for use as an external positive and negative assayed control to monitor the performance of the qualitative detection of yeast, Gram positive and Gram negative bacteria, as well as associated antimicrobial resistance genes, by the BioFire FilmArray Blood Culture Identification 2 (BCID2) Panel on FilmArray systems. Control 1 - GN: Gram negative bacteria: Acinetobacter colcoaceticus-baumannii complex, Bacteroides fragilis, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae group, Proteus spp., Salmonella spp., Serratia marcescens, Haemophilus influenza, Neisseria meningitides, Pseudomonas aeruginosa, Stenotrophomonas maltophilia; antimicrobial resistance genes: KPC, CTX-M, IMP, NDM, OXA-48-like, VIM, mcr-1. Control 2 - GPY: Gram positive bacteria: Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunesis, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes; yeast: Candida albicans, Candida auris, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans/gatti; antimicrobial resistance genes: mecA/C and MREJ, vanA/B. This product is not intended to replace manufacturer controls provided with the device.

# B Indication(s) for Use:

See Indications for Use below.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

For in vitro diagnostic use only

# D Special Instrument Requirements:

The MDx-Chex for BCID2 was evaluated on the FilmArray 2.0 and FilmArray Torch instruments.

# A Device Description:

Streck Molecular Control (SMC; trade name: MDx-Chex for BCID2) is an external positive and negative assayed control consisting of two levels of control, Control 1- Gram negative (GN) and Control 2- GPY (Gram positive and yeast). Each control contains stabilized human leukocytes and erythrocytes, and inactivated bacteria in a simulated blood culture media. Both controls contain target sequence in intact and inactivated bacterial and yeast cells, as well as antimicrobial gene targets (in relevant pathogens that are intact and inactivated) that are detected by the BioFire FilmArray Blood Culture Identification 2 (BCID2) Panel on FilmArray systems. MDxChex for BCID2 is a full-process, cellular-based control for the BioFire BCID2 Panel that evaluates the entire analytical process including sample lysis, nucleic acid isolation and purification, amplification, detection, and analysis, as well as the impact of PCR inhibitors and preanalytical variables. Each control for the MDx-Chex for BCID2 is processed separately according to the BioFire BCID2 Panel Package Insert for patient samples.

B Pathogens and antimicrobial resistance genes found in MDx-Chex for BCID2 and detected by BioFire BCID2 Panel assay   

<table><tr><td rowspan=1 colspan=2>Antimicrobial resistance genes</td></tr><tr><td rowspan=1 colspan=1>CTX-M</td><td rowspan=1 colspan=1>mecA/C and MREJ (MRSA)</td></tr><tr><td rowspan=1 colspan=1>IMP</td><td rowspan=1 colspan=1>NDM</td></tr><tr><td rowspan=1 colspan=1>KPC</td><td rowspan=1 colspan=1>OXA-48-like</td></tr><tr><td rowspan=1 colspan=1>mcr-1</td><td rowspan=1 colspan=1>vanA/B</td></tr><tr><td rowspan=1 colspan=1>mecA/C</td><td rowspan=1 colspan=1>VIM</td></tr><tr><td rowspan=1 colspan=2>Gram Positive Bacteria</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecalis</td><td rowspan=1 colspan=1>Streptococcus spp.</td></tr><tr><td rowspan=1 colspan=1>Enterococcus faecium</td><td rowspan=1 colspan=1>Streptococcus agalactiae (Group B)</td></tr><tr><td rowspan=1 colspan=1>Listeria monocytogenes</td><td rowspan=1 colspan=1>Streptococcus pneumoniae</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus spp.</td><td rowspan=1 colspan=1>Streptococcus pyogenes (Group A)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus epidermidis</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus lugdunensis</td><td rowspan=1 colspan=1>EY</td></tr><tr><td rowspan=1 colspan=2>Gram Negative Bacteria</td></tr><tr><td rowspan=1 colspan=1>Acinetobacter calcoaceticus-baumannii complex</td><td rowspan=1 colspan=1>Enteric bacteria</td></tr><tr><td rowspan=1 colspan=1>Bacteroides fragilis</td><td rowspan=1 colspan=1>Enterobacter cloacae complex</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenzae</td><td rowspan=1 colspan=1>Escherichia coli</td></tr><tr><td rowspan=1 colspan=1>Neisseria meningitidis</td><td rowspan=1 colspan=1>Klebsiella aerogenes</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>Klebsiella oxytoca</td></tr><tr><td rowspan=1 colspan=1>Stenotrophomonas maltophilia</td><td rowspan=1 colspan=1>Klebsiella pneumoniae group</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Salmonella spp</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Serratia marcescens</td></tr><tr><td rowspan=1 colspan=2>Yeast</td></tr><tr><td rowspan=1 colspan=1>Candida albicans</td><td rowspan=1 colspan=1>Candida parapsilosis</td></tr><tr><td rowspan=1 colspan=1>Candida auris</td><td rowspan=1 colspan=1>Candida tropicalis</td></tr><tr><td rowspan=1 colspan=1>Candida glabrata</td><td rowspan=1 colspan=1>Cryptococcus neoformans/gattii</td></tr><tr><td rowspan=1 colspan=1>Candida krusei</td><td rowspan=1 colspan=1></td></tr></table>

C Principle of Operation: Not Applicable

V Substantial Equivalence Information:

A Predicate Device Name(s): FilmArray BCID2 Control Panel M416 B Predicate 510(k) Number(s): K200010

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">K212576</td><td colspan="1" rowspan="1">K200010</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">MDx-Chex for BCID2</td><td colspan="1" rowspan="1">FilmArray BCID2 Control PanelM416</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/IndicationsFor Use</td><td colspan="1" rowspan="1">MDx-Chex for BCID2 is intended foruse as an external positive and negativeassayed control to monitor theperformance of the qualitative detectionof yeast, Gram positive and Gramnegative bacteria, as well as associatedantimicrobial resistance genes, by theBioFire FilmArray Blood CultureIdentification 2 (BCID2) Panel onFilmArray systems. Control 1 - GN:Gram negative bacteria: Acinetobactercolcoaceticus-baumannii complex,Bacteroides fragilis, Enterobactercloacae complex, Escherichia coli,Klebsiella aerogenes, Klebsiellaoxytoca, Klebsiella pneumoniae group,Proteus spp., Salmonella spp., Serratiamarcescens, Haemophilus influenza,Neisseria meningitides, Pseudomonasaeruginosa, Stenotrophomonasmaltophilia; antimicrobial resistancegenes: KPC, CTX-M, IMP, NDM,OXA-48-like, VIM, mcr-1. Control 2 -GPY: Gram positive bacteria:Enterococcus faecalis, Enterococcusfaecium, Listeria monocytogenes,</td><td colspan="1" rowspan="1">FilmArray BCID2 Control PanelM416 is intended for use as anexternal positive and negative assayedquality control to monitor theperformance of in vitro laboratorynucleic acid testing procedures for thequalitative detection of antimicrobialresistance genes: CTX-M, IMP, KPC,mcr-1, mecA/C, mecA/C and MREJ(MRSA), NDM, OXA-48-like,vanA/B, VIM; Gram positive andGram-negative bacteria: Enterococcusfaecalis, Enterococcus faecium,Listeria monocytogenes,Staphylococcus spp., Staphylococcusaureus, Staphylococcus epidermidis,Staphylococcus lugdunensis,Streptococcus spp., Streptococcusagalactiae (Group B), Streptococcuspneumoniae, Streptococcus pyogenes(Group A), Acinetobactercalcoaceticus baumannii complex,Bacteroides fragilis, Enteric bacteria,Enterobacter cloacae complex,Escherichia coli, Klebsiellaaerogenes, Klebsiella oxytoca,</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Staphylococcus aureus, Staphylococcusepidermidis, Staphylococcus lugdunesis,Streptococcus agalactiae, Streptococcuspneumonia, Streptococcus pyogenes;yeast: Candida albicans, Candida auris,Candida glabrata, Candida krusei,Candida parapsilosis, Candidatropicalis, Cryptococcusneoformans/gatti; antimicrobialresistance genes: mecA/C and MREJ,vanA/B. This product is not intended toreplace manufacturer controls providedwith the device.</td><td colspan="1" rowspan="1">Klebsiella pneumoniae group, Proteusspp., Salmonella spp., Serratiamarcescens, Haemophilus influenzae,Neisseria meningitidis, Pseudomonasaeruginosa and Stenotrophomonasmaltophilia; and yeast pathogens:Candida albicans, Candida auris,Candida glabrata, Candida krusei,Candida parapsilosis, Candidatropicalis, and Cryptococcusneoformans/gattii on the BioFireBlood Culture Identification 2(BCID2) Panel assay on FilmArraysystems.FilmArray BCID2 Control PanelM416 is composed of synthetic DNAspecifically designed for and intendedto be used solely with the BioFireBCID2 Panel assay. This product isnot intended to replace manufacturercontrols provided with the device.</td></tr><tr><td colspan="1" rowspan="1">Physical Format</td><td colspan="1" rowspan="1">Ready-to-Use Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Direction for Use</td><td colspan="1" rowspan="1">Process like patient sample</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Number oftargets monitoredin one assay</td><td colspan="1" rowspan="1">Multiple, &gt;30 targets</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Intact inactivated bacteria, humanerythrocytes and leukocytes, andrelevant components of blood culturemedia</td><td colspan="1" rowspan="1">Synthetic DNA</td></tr><tr><td colspan="1" rowspan="1">Assay StepsMonitored</td><td colspan="1" rowspan="1">Lysis, nucleic acidisolation/purification/PCR inhibitorremoval, amplification, detection,identification/data reporting</td><td colspan="1" rowspan="1">Reverse transcription, amplification,detection</td></tr></table>

# VI Standards/Guidance Documents Referenced:

None Referenced

VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

A multi-site reproducibility study was performed with the MDx-Chex for BCID2 at four different study sites using three lots of MDx-Chex for BCID2 panel per test site. Testing consisted of a total of 20 samples being analyzed per lot. Eleven operators particpated in the study with 2-4 operator per site. The study was performed on FilmArray instrument 2.0 (used at test sites 1 and 4) and FilmArray Torch systems (used at test sites 1, 2, and 3). A total of 240 external controls were tested. Of the 240 controls tested, 10 positive controls were false negatives, however upon retesting were confirmed as positive controls. As part of the workflow, if an unexpected result is observed for one or more targets within a given run, that sample may be rerun no more than one time to determine if the correct results are obstained for the targets with unexpected results during the first run. Also, of the 10 false negatives, 6 were for not detecting the mecA/C and MREJ antimicrobil resistance gene across three of the four test sites. This resulted in a positive percent agreement of $9 5 . 8 \%$ $( \mathrm { n } { = } 2 3 0 / 2 4 0 )$ ); see Table 1 below. Also, of the 240 controls tested, 1 negative control was false positive and upon retesting was confirmed as a negative control. This resulted in a negative percent agreement of $9 9 . 6 \%$ $( \mathrm { n } { = } 2 3 9 / 2 4 0 )$ ; see Table 2 below.

Table 1: Streck Molecular Control (SMC) Reproducibility Summary: Positive Percent Agreement   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=1 colspan=2>Site #1</td><td rowspan=1 colspan=2>Site #2</td><td rowspan=1 colspan=2>Site #3</td><td rowspan=1 colspan=2>Site #4</td><td rowspan=2 colspan=1>PercentAgreement(all sitescombined)</td></tr><tr><td rowspan=1 colspan=1>#ObservedResults/#ExpectedResults </td><td rowspan=1 colspan=1>PositivePercentAgreement</td><td rowspan=1 colspan=1>#ObservedResults/#ExpectedResults </td><td rowspan=1 colspan=1>PositivePercentAgreement</td><td rowspan=1 colspan=1>#ObservedResults/#Expected Results 1</td><td rowspan=1 colspan=1>PositivePercentAgreement</td><td rowspan=1 colspan=1>#ObservedResults/#ExpectedResults </td><td rowspan=1 colspan=1>PositivePercentAgreement</td></tr><tr><td rowspan=1 colspan=1>SMC Level1 (GN) andLevel 2(GPY),Combined</td><td rowspan=1 colspan=1>59/60*</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>57/60*</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>58/60*</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>56/60*</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>95.8%(230/240)</td></tr></table>

$^ { * } 1 0$ Positive controls gave initial false negative results; all produced the correct results upon a single retest. 1 Expected result for the Positive Control is positive. Denominator $=$ total # of results for Level 1-GN and Level 2-GPY controls. $\mathrm { G P Y = }$ Gram-positive and yeast control, $\mathrm { G N } =$ Gram-negative control.

Table 2: Streck Molecular Control (SMC) Reproducibility Summary: Negative Percent Agreement   

<table><tr><td rowspan=2 colspan=1>Category</td><td rowspan=1 colspan=2>Site #1</td><td rowspan=1 colspan=2>Site #2</td><td rowspan=1 colspan=2>Site #3</td><td rowspan=1 colspan=2>Site #4</td><td rowspan=1 colspan=1>Percent</td></tr><tr><td rowspan=1 colspan=1>#ObservedResults/#ExpectedResult 1</td><td rowspan=1 colspan=1>NegativeercentAgreement</td><td rowspan=1 colspan=1>#ObservedResults/#ExpectedResults 1</td><td rowspan=1 colspan=1>NegativePercentAgreement</td><td rowspan=1 colspan=1>#ObservedResults/#ExpectedRe sults 1</td><td rowspan=1 colspan=1>NegativePercentAgreement</td><td rowspan=1 colspan=1>#ObservedResults/#ExpectedResults 1</td><td rowspan=1 colspan=1>NegativePPercentAgreement</td><td rowspan=1 colspan=1>Agreement(all sitescombined)</td></tr><tr><td rowspan=1 colspan=1>SMC Level1 (GN) andLevel 2(GPY),Combined</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>59/60*</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>99.6%(239/240)</td></tr></table>

\* 1 Negative control gave initial false positive result and produced correct result upon a single retest. 1 Expected result for the Negative Control is negative. Denominator $=$ total $\#$ of results for Level 1-GN and Level 2-GPY controls. $\mathrm { G P Y = }$ Gram-positive and yeast control, $\mathrm { G N } =$ Gram-negative control.

The results suggest that there are no significant differences between different users and different study sites on different days. External reproducibility studies for the MDx-Chex for BCID2 are acceptable.

Precision

An internal precision study for the MDx-Chex for BCID2 was conducted over 20 nonconsequetive days by testing three different control lots. Each lot was tested on two FilmArray Torch instruments. A total of 20 samples were tested per lot and level (Level 1- GN and Level 2- GPY) by four operators. Samples and pouches were prepared according to BCID2 and control instructions. All controls gave correct results except for 6 positive control that gave false negative results, however upon retesting was confirmed as positive controls; This resulted in a positive percent agreement of $9 5 \%$ $\left( \mathrm { n { = } 1 } 1 4 / 1 2 0 \right)$ and a negative percent agreement of $100 \%$ $( \mathrm { n } { = } 1 2 0 / 1 2 0 )$ ); see Tables 3 and 4 below.

Table 3: Streck Molecular Control (SMC) Precision Summary: Positive Percent Agreement   

<table><tr><td rowspan=1 colspan=1>Category</td><td rowspan=1 colspan=1># Observed Results/# Expected Results 1</td><td rowspan=1 colspan=1>Positive PercentAgreement</td></tr><tr><td rowspan=1 colspan=1>SMC Level 1-GN andLevel 2-GPY,Combined</td><td rowspan=1 colspan=1>114/120*</td><td rowspan=1 colspan=1>95%</td></tr></table>

$^ { * } 6$ Positive controls gave initial false negative results; all produced the correct results upon a single retest. 1 Expected result for the Positive Control is positive. Denominator $=$ total # of results for GN (Level 1) and GPY (Level 2) controls. $\mathrm { G P Y = }$ grampositive and yeast control, $\mathrm { G N } =$ gram negative control.

Table 4: Streck Molecular Control (SMC) Precision Summary: Negative Percent Agreement   

<table><tr><td rowspan=1 colspan=1>Category</td><td rowspan=1 colspan=1># Observed Results/# Expected Results 1</td><td rowspan=1 colspan=1>Negative PercentAgreement</td></tr><tr><td rowspan=1 colspan=1>SMC Level 1- GN andLevel 2-GPY,Combined</td><td rowspan=1 colspan=1>120/120</td><td rowspan=1 colspan=1>100%</td></tr></table>

Expected result for the Negative Control is negative. Denominator $=$ total $\#$ of results for GN (Level 1) and GPY (Level 2) controls. $\mathrm { G P Y = }$ gram-positive and yeast control, $\mathrm { G N } =$ gram negative control.

There appears to be no significant differences in the detection of the control organisms and antimicrobial resistance genes when testing different control lots on different days. Precision studies are acceptable.

# Within-run Testing

Within-run precision was demonstrated in a separate study using a single lot of MDx-Chex for BCID2 analyzed on a single day. Six control vials were tested for each control level (Level 1-GN and Level 2- GPY). The samples were analyzed on the FilmArray Torch instrument. The results are shown in Tables 5 and 6 below:

Table 5: Streck Molecular Control (SMC) Within-run Precision Summary: Positive Percent Agreement   

<table><tr><td>Category</td><td>SMC Lot</td><td># Observed Results/ # Expected Results 1</td><td>Positive Percent Agreement</td></tr><tr><td>SMC Level 1(GN) and Level 2 (GPY),</td><td>21129</td><td>12/12</td><td>100%</td></tr><tr><td>Combined</td><td></td><td></td><td></td></tr></table>

1 Expected result for the Positive Control is positive. Denominator $=$ total # of expected positive result sets for Level 1-GN and Level 2-GPY controls. $\mathrm { G N } =$ gram negative control, $\mathrm { G P Y = }$ gram-positive and yeast control.

Table 6: Streck Molecular Control (SMC) Within-run Precision Summary: Negative Percent Agreement   

<table><tr><td rowspan=1 colspan=1>Category</td><td rowspan=1 colspan=1>SMC Lot</td><td rowspan=1 colspan=1># Observed Results/# Expected Results 1</td><td rowspan=1 colspan=1>Negative PercentAgreement</td></tr><tr><td rowspan=1 colspan=1>SMC Level 1(GN)and Level 2 (GPY),Combined</td><td rowspan=1 colspan=1>21129</td><td rowspan=1 colspan=1>12/12</td><td rowspan=1 colspan=1>100%</td></tr></table>

1 Expected result for the Negative Control is negative. Denominator $=$ total # of expected negative result sets for Level 1-GN and Level 2-GPY controls. $\mathrm { G N } =$ gram negative control, $\mathrm { G P Y = }$ gram-positive and yeast control.

Within-run reproducibility studies for the MDx-Chex for BCID2 are acceptable.

# Lot-to-lot Testing

Lot-to-lot reproducibility was demonstrated by testing three lots of MDx-Chex for BCID2. Samples were prepared and analyzed on the BioFire FilmArray Torch per SMC and BCID2 Instructions for Use. Of the positive controls, one sample gave a false negative result that was confirmed as a positive control upon retesting. Results are shown in Tables 7 and 8 below.

Table 7: Streck Molecular Control (SMC) Lot-to-Lot Precision Summary: Positive Percent Agreement   

<table><tr><td rowspan=1 colspan=1>Category</td><td rowspan=1 colspan=1>SMC Lot</td><td rowspan=1 colspan=1># Observed Results/#Expected Results 1</td><td rowspan=1 colspan=1>Positive PercentAgreement</td></tr><tr><td rowspan=3 colspan=1>SMC Level 1(GN)and Level 2 (GPY),Combined</td><td rowspan=1 colspan=1>20363</td><td rowspan=1 colspan=1>11/12*</td><td rowspan=1 colspan=1>91.7%</td></tr><tr><td rowspan=1 colspan=1>20366</td><td rowspan=1 colspan=1>12/12</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>21129</td><td rowspan=1 colspan=1>12/12</td><td rowspan=1 colspan=1>100%</td></tr></table>

$^ \ast 1$ Positive control gave an initial false negative result; it produced the correct result upon a single retest. 1 Expected result for the Positive Control is positive. Denominator $=$ total $\#$ of expected positive result sets for Level 1-GN and Level 2-GPY controls. $\mathrm { G N } =$ gram negative control, $\mathrm { G P Y = }$ gram-positive and yeast control.

Table 8: Streck Molecular Control (SMC) Lot-to-Lot Precision Summary: Negative Percent Agreement   

<table><tr><td colspan="1" rowspan="1">Category</td><td colspan="1" rowspan="1">SMC Lot</td><td colspan="1" rowspan="1"># Observed Results/# Expected Results 1</td><td colspan="1" rowspan="1">NegativePercentAgreement</td></tr><tr><td colspan="1" rowspan="2">SMC Level 1(GN)and Level 2 (GPY),Combined</td><td colspan="1" rowspan="1">20363</td><td colspan="1" rowspan="1">12/12</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">20366</td><td colspan="1" rowspan="1">12/12</td><td colspan="1" rowspan="1">100%</td></tr><tr><td></td><td>21129</td><td>12/12</td><td>100%</td></tr></table>

1 Expected result for the Negative Control is negative. Denominator $=$ total $\#$ of expected negative result sets for Level 1-GN and Level 2-GPY controls. $\mathrm { G N } =$ gram negative control, $\mathrm { G P Y = }$ gram-positive and yeast control.

Lot-to-Lot reproducibility studies for the MDx-Chex for BCID2 are acceptable.

2. Linearity: Not Applicable

3. Analytical Specificity/Interference: Not Applicable

4. Assay Reportable Range: Not Applicable

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Open Vial Stability

A real-time open-vial stability study is ongoing using three lots of MDx-Chex for BCID2. Samples were stored in a controlled refrigerated $\left( 2 \mathrm { - } 8 ^ { \circ } \mathrm { C } \right)$ or controlled room temperature (20- $2 5 ^ { \circ } \mathrm { C } )$ . Ten samples per lot per level is being tested at day 0 (baseline a total of 60 samples per temperature) and a minimum of 61 days for each lot and storage condition. Each lot was tested for different duration (Lot 20263 was tested for 77 days, Lot 20366 was tested for 75 days and Lot 21129 was tested for 63 days) and therefore the shelf-life in Table 9 was denoted as day $6 1 ^ { + }$ for each temperature tested. At baseline, 120 total tubes were tested then divided in half for storage at the two temperatures stated above. All samples are analyzed on the FilmArray Torch instrument. The data presented here are to support a 60 day open-vial stability claim and data to support a longer open-vial stability claim will be submitted at a later date. The data for the $6 1 ^ { + }$ day study showed that at baseline, there were five false negatives and three false positive, that upon retesting were correctly confirmed as postive controls and negative controls, respectively. The data also showed that on day $6 1 ^ { + }$ , three samples, stored at $2 0 { - } 2 5 ^ { \circ } \mathrm { C }$ , were false negatives and were correctly confirmed as postive controls upon retesting. Therefore, giving an overall PPA and NPA are $9 6 . 9 \%$ and $9 9 . 2 \%$ , respectively. The results are shown in Tables 9 and 10 below.

Table 9. Streck Molecular Control (SMC) Open-Vial Stability: Positive Percent Agreement   

<table><tr><td colspan="1" rowspan="1">Shelf-Life</td><td colspan="1" rowspan="1">StorageTemperature</td><td colspan="1" rowspan="1">#Observed Results/#Expected Results 1</td><td colspan="1" rowspan="1">PositivePercentAgreement</td><td colspan="1" rowspan="1">PPA ≥ 90%Acceptance</td></tr><tr><td colspan="1" rowspan="1">Day 0*</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">115/120**</td><td colspan="1" rowspan="1">95.8%</td><td colspan="1" rowspan="1">Pass</td></tr><tr><td colspan="1" rowspan="1">Day 61+</td><td colspan="1" rowspan="1">2-8°</td><td colspan="1" rowspan="1">60/60</td><td colspan="1" rowspan="1">100%</td><td colspan="1" rowspan="1">Pass</td></tr><tr><td colspan="1" rowspan="1">Day 61+</td><td colspan="1" rowspan="1">20-25°C</td><td colspan="1" rowspan="1">57/60***</td><td colspan="1" rowspan="1">95%</td><td colspan="1" rowspan="1">Pass</td></tr></table>

1 Expected result for the Positive Control is positive. Denominator $=$ total combined # of expected positive results for Level 1-GN and Level 2- GPY controls. $\mathrm { G P Y = }$ gram-positive and yeast control, $\mathrm { G N } =$ gram negative control. $^ { * } 1 2 0$ tubes were completed for Day 0 (baseline). Tubes were divided in half for storage. $^ { * * } 5$ Positive controls gave false negative results on the first test; all reruns produced correct results upon a single retest. $* * * 3$ positive controls gave false negative results on the first test; all reruns produced correct results upon a single retest. $^ +$ Indicates that each lot was tested for at least 61 days. Lot 20263 (77 days); Lot 20366 (75 days); and Lot 21129 (63 days).

Table 10. Streck Molecular Control (SMC) Open-Vial Stability: Negative Percent Agreement   

<table><tr><td rowspan=1 colspan=1>Shelf-Life</td><td rowspan=1 colspan=1>StorageTemperature</td><td rowspan=1 colspan=1>#Observed Results/#Expected Results 1</td><td rowspan=1 colspan=1>NegativePercentAgreement</td><td rowspan=1 colspan=1>NPA ≥ 90%Acceptance</td></tr><tr><td rowspan=1 colspan=1>Day 0*</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>117/120**</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Day 61+</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Day 61+</td><td rowspan=1 colspan=1>20-25°C</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>Pass</td></tr></table>

1 Expected result for the Negative Control is negative. Denominator $=$ total combined $\#$ of expected negative results for Level 1-GN and Level 2- GPY controls. $\mathrm { G P Y = }$ Gram-positive and yeast control, $\mathrm { G N } =$ Gram-negative control. $^ { * } 1 2 0$ tubes were completed for Day 0 (baseline). Tubes were divided in half for storage. $^ { * * } 3$ negative controls gave false positive results on the first test; all reruns produced correct results upon a single retest. + Indicates that each lot was tested for at least 61 days. Lot 20263 (77 days); Lot 20366 (75 days); and Lot 21129 (63 days).

The data for the ongoing open-vial stability study support the conclusion that MDx-Chex for BCID2 has an open-vial stability of 60 days when stored at $2 { - } 2 5 ^ { \mathrm { { \circ } C } }$ .

# Closed-vial Stability

A real-time closed-vial stability study is ongoing using three lots of MDx-Chex for BCID2. Samples were stored in a controlled refrigerated $( 2 { - } 8 ^ { \circ } \mathrm { C } )$ or controlled room temperature (20- $2 5 ^ { \circ } \mathrm { C } )$ ). Ten samples per lot per level is being tested at day 0 (baseline a total of 60 samples per temperature) and a minimum of 61 days $( 6 0 ^ { + } )$ for each lot and storage condition. At baseline, 120 total tubes were tested then divided in half for storage at the two temperatures stated above. All samples are analyzed on the FilmArray Torch instrument. The data presented here are for at least 61 days and data to support a longer closed-vial stability claim will be submitted at a later date. The same baseline data used for the open-vial stability study above was used here. The closed-vial stability study data showed that on day $6 1 ^ { + }$ at refrigerated temperature, two samples were false negatives and one sample was false positive, that upon retesting were correctly confirmed as positive controls and negative control, respectively. The data also showed that on day $6 1 ^ { + }$ at room temperature, one sample was false positive that was correctly confirmed as negative control upon retesting. Therefore, the overall PPA and NPA are $9 7 . 5 \%$ and $9 8 \%$ , respectively. The results are shown in Tables 11 and 12 below.

Table 11. Streck Molecular Control (SMC) Close-Vial Stability: Positive Percent Agreement

<table><tr><td rowspan=1 colspan=1>Shelf-Life</td><td rowspan=1 colspan=1>StorageTemperature</td><td rowspan=1 colspan=1>#Observed Results/#Expected Results 1</td><td rowspan=1 colspan=1>PositivePercentAgreement</td><td rowspan=1 colspan=1>PPA ≥ 90%Acceptance</td></tr><tr><td rowspan=1 colspan=1>Day 0*</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>115/120**</td><td rowspan=1 colspan=1>95.8%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Day 61+</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>58/60***</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Day 61+</td><td rowspan=1 colspan=1>20-25°</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>Pass</td></tr></table>

1 Expected result for the Positive Control is positive. Denominator $=$ total combined # of expected positive results for Level 1-GN and Level 2- GPY controls. $\mathrm { G P Y = }$ gram-positive and yeast control, $\mathrm { G N } =$ gram negative control. $^ { * } 1 2 0$ tubes were completed for Day 0 (baseline). Tubes were divided in half for storage. $^ { * * } 5$ Positive controls gave false negative results on the first test; all reruns produced correct results upon a single retest. $* * * ~ 2$ 2 Positive controls gave false negative results on the first test; all reruns produced correct results upon a single retest. + Indicates that each lot was tested for at least 61 days. Lot 20263 (77 days); Lot 20366 (75 days); and Lot 21129 (63 days).

Table 12. Streck Molecular Control (SMC) Close-Vial Stability: Negative Percent Agreement   

<table><tr><td rowspan=1 colspan=1>Shelf-Life</td><td rowspan=1 colspan=1>StorageTemperature</td><td rowspan=1 colspan=1>#Observed Results/#Expected Results 1</td><td rowspan=1 colspan=1>NegativePercentAgreement</td><td rowspan=1 colspan=1>NPA ≥ 90%Acceptance</td></tr><tr><td rowspan=1 colspan=1>Day 0*</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>117/120**</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Day 61+</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>59/60***</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>Pass</td></tr><tr><td rowspan=1 colspan=1>Day 61+</td><td rowspan=1 colspan=1>20-25°C</td><td rowspan=1 colspan=1>59/60****</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>Pass</td></tr></table>

1 Expected result for the Negative Control is negative. Denominator $=$ total combined $\#$ of expected negative results for Level 1-GN and Level 2 GPY controls. $\mathrm { G P Y = }$ Gram-positive and yeast control, $\mathrm { G N } =$ Gram-negative control. $^ { * } 1 2 0$ tubes were completed for Day 0 (baseline). Tubes were divided in half for storage. $^ { * * } 3$ negative controls gave false positive results on the first test; all reruns produced correct results upon a single retest. $^ { * * * 1 }$ negative control gave a false positive result on the first test; all reruns produced correct results upon a single retest. $^ { \ast \ast \ast \ast }$ 1 negative control gave false positive result on the first test; rerun produced correct result upon a single retest. + Indicates that each lot was tested for at least 61 days. Lot 20263 (77 days); Lot 20366 (75 days); and Lot 21129 (63 days).

The data for the ongoing closed-vial stability study support the conclusion that MDx-Chex for BCID2 has a closed-vial stability of 60 days when stored at $2 { - } 2 5 ^ { \circ } \mathrm { C }$ .

# Real-time Stability Testing

Real-time stability studies are ongoing to support product claims for the MDx-Chex for BCID2. Real-time stability study protocols and acceptance criteria were reviewed and found to be acceptable.

# Shipping Stability

A shipping stability study was performed to validate the stability of MDx-Chex for BCID2 during shipment. Using a single lot, two sets of samples were simulated into a summer or winter months profile over five days. Temperature stress conditions for Summer followed a

120-hour exposure period with the following temperature profile: 5h at $2 2 \mathrm { { } ^ { \circ } C }$ , 14h at $2 6 \mathrm { { } ^ { \circ } C }$ , $5 . 5 \mathrm { h }$ at $2 2 \mathrm { { } ^ { \circ } C }$ , $5 . 5 \mathrm { h }$ at $2 5 \mathrm { { ^ \circ C } }$ , $1 0 \mathrm { { h } }$ at $2 2 \mathrm { { } ^ { \circ } C }$ , 2h at $4 0 \%$ , $1 5 \mathrm { h }$ at $2 9 \mathrm { { } ^ { \circ } C }$ , $5 \mathrm { h }$ at $4 0 \%$ , $1 7 . 5 \mathrm { h }$ at $2 6 \mathrm { { } ^ { \circ } C }$ , $1 1 . 5 \mathrm { h }$ at $2 9 \mathrm { { } ^ { \circ } C }$ , $1 0 \mathrm { { h } }$ at $2 2 \mathrm { { } ^ { \circ } C }$ , $7 . 5 \mathrm { h }$ at $3 0 \mathrm { { } ^ { \circ } C }$ , and $1 1 . 5 \mathrm { h }$ at $2 4 \mathrm { { } ^ { \circ } C }$ . Temperature stress conditions for Winter followed a 120-hour exposure with the following temperature profile: 5h at $2 2 \mathrm { { } ^ { \circ } C }$ , 14h at $1 5 \mathrm { ^ \circ C }$ , $5 . 5 \mathrm { h }$ at $2 2 \mathrm { { } ^ { \circ } C }$ , $5 . 5 \mathrm { h }$ at $1 7 \mathrm { { } ^ { \circ } C }$ , $1 0 \mathrm { { h } }$ at $2 2 \mathrm { { } ^ { \circ } C }$ , 2h at $- 1 0 \mathrm { { } ^ { \circ } C }$ , 15h at $1 0 ^ { \circ } \mathrm { C }$ , 5h at $- 1 0 \mathrm { { } ^ { \circ } C }$ , $1 7 . 5 \mathrm { h }$ at $1 5 \mathrm { { ^ \circ C } }$ , 11.5h at $1 0 \mathrm { { } ^ { \circ } C }$ , $1 0 \mathrm { { h } }$ at $2 2 \mathrm { { } ^ { \circ } C }$ , $7 . 5 \mathrm { h }$ at $8 \mathrm { { } ^ { \circ } C }$ , and $1 1 . 5 \mathrm { h }$ at $1 8 \mathrm { { } ^ { \circ } C }$ . After temperature stress, samples were then incubated at $2 { - } 8 ^ { \circ } \mathrm { C }$ for a week prior to being tested on the FilmArray Torch instrument. Ten samples were analyzed for each control (Level 1 and Level 2) for a total of 20 samples analyzed. Data showed that analysis using the summer profile resulted in one false negative and one false positive that upon retesting was correctly confirmed as a positive control and a negative control, respectively. Therefore, the overall PPA and NPA were $9 7 . 5 \%$ individually. Results are presented in Tables 13 and 14 below.

Table 13: Summary of Shipping Study for the Streck Molecular Control MDx-Chex: Positive Agreement   

<table><tr><td rowspan=1 colspan=1>Category</td><td rowspan=1 colspan=1># Expected results / #Tested 1</td><td rowspan=1 colspan=1>Positive PercentAgreement</td></tr><tr><td rowspan=1 colspan=1>Summer</td><td rowspan=1 colspan=1>19/20*</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>Winter</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td></tr></table>

1 Expected result for the Positive Control is positive. $^ \ast 1$ Positive control gave initial false negative result; it produced the correct result upon a single retest.

Table 14: Summary of Shipping Study for the Streck Molecular Control MDx-Chex: Negative Agreement   

<table><tr><td rowspan=1 colspan=1>Category</td><td rowspan=1 colspan=1># Expected results / #Tested 1</td><td rowspan=1 colspan=1>Negative PercentAgreement</td></tr><tr><td rowspan=1 colspan=1>Summer</td><td rowspan=1 colspan=1>19/20*</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>Winter</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td></tr></table>

1 Expected result for the Negative Control is negative. $^ \ast 1$ Negative control gave initial false positive result; it produced correct result upon a single retest.

The data support a claim that MDx-Chex for BCID2 remains funtional after exposure to extreme temperature that may occur during shipping.

6. Detection Limit: Not Applicable

7. Assay Cut-Off: Not Applicable

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Not Applicable

2. Matrix Comparison:

The matrix of MDx-Chex for BCID2 is made of stabilized blood components (erythrocytes and leukocytes) in a simulated blood culture media. Since the matrix is not identical to that of the routine BCID2 assay sample, blood culture media, a test was performed to investigate the effect of the matrix on the assay.

To confirm that the matrix has no effect on the assay or control, inactivated Streptococcus pneumoniae was spiked into the MDx-Chex for BCID2 matrix as well as into BD BACTEC Plus Aerobic/F culture vial with negative whole blood to simulate a clinical sample. These samples were then tested in triplicate using the BCID2 Panel. Three replicates of each simulated matrix with no spike-in organism were also tested to serve as negative controls. Samples were analyzed on FilmArray Torch intrument. The results showed PPA and NPA of $100 \%$ and results are shown in Tables 15 and 16 below.

Table 15: Effect of Streck Molecular Control MDx-Chex and Clinical Samples Spiked with S. pneumonia, Tested on BCID-2 panel   

<table><tr><td rowspan=1 colspan=1>Matrix type</td><td rowspan=1 colspan=1># Expected results / #tested 1</td><td rowspan=1 colspan=1>Percent Agreement</td></tr><tr><td rowspan=1 colspan=1>MDx-Chex, PositiveMatrix</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Clinical, PositiveMatrix</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td></tr></table>

1 Expected result for the Positive Matrix is positive.

Table 16: Effect of Negative Streck Molecular Control MDx-Chex and Negative Clinical Samples, Tested on BCID-2 panel   

<table><tr><td rowspan=1 colspan=1>Matrix type</td><td rowspan=1 colspan=1># Expected results /#tested 1</td><td rowspan=1 colspan=1>Percent Agreement</td></tr><tr><td rowspan=1 colspan=1>MDx-Chex, NegativeMatrix</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Clinical, NegativeMatrix</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100%</td></tr></table>

1 Expected result for Negative Matrix is negative.

The results show that samples prepared with the MDx-Chex for BCID2 matrix showed no inhibition and/or false negative results when used with the FilmArray BCID2 panel. The data also support the conclusion that the SMC MDx-Chex performs identically to a clinical BCID2 panel sample, positive blood culture sample.

# C Clinical Studies:

1. Clinical Sensitivity: Not Applicable

2. Clinical Specificity: Not Applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not Applicable

# D Clinical Cut-Off:

Not Applicable

# E Expected Values/Reference Range:

MDx-Chex for BCID2 is a qualitative control and the expected results are listed in Table 17 below.

Table 17 – Pathogens and antimicrobial resistance genes detected by MDx-Chex for BCID2 Control   

<table><tr><td colspan="3" rowspan="1">Gram-Negative Bacteria</td></tr><tr><td colspan="1" rowspan="1">Pathogen</td><td colspan="1" rowspan="1">MDx-Chex for BCID2Control 1 - GN</td><td colspan="1" rowspan="1">MDx-Chex for BCID2Control 2 - GPY</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter colcoaceticus-baumanniicomplex</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Enterobacter cloacae complex</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae group</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Proteus spp.</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Salmonella spp.</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzae</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Neisseria meningitides</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">Stenotrophomonas maltophilia</td><td colspan="1" rowspan="1">Detected</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td></td><td colspan="1" rowspan="1">Gram-Positive Bacteria</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Pathogen</td><td colspan="1" rowspan="1">MDx-Chex for BCID2Control 1 - GN</td><td colspan="1" rowspan="1">MDx-Chex for BCID2Control 2 - GPY</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalis</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecium</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Listeria monocytogenes</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus lugdunesis</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Streptococcus agalactiae</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pyogenes</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td></td><td colspan="2" rowspan="1">Yeast</td></tr><tr><td colspan="1" rowspan="1">Pathogen</td><td colspan="1" rowspan="1">MDx-Chex for BCID2Control 1 - GN</td><td colspan="1" rowspan="1">MDx-Chex for BCID2Control 2 - GPY</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Candida auris</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Candida glabrata</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Candida krusei</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Candida parapsilosis</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Candida tropicalis</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr><tr><td colspan="1" rowspan="1">Cryptococcus neoformans/gatti</td><td colspan="1" rowspan="1">Not detected</td><td colspan="1" rowspan="1">Detected</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Antimicrobial Resistance Genes</td></tr><tr><td rowspan=1 colspan=1>Gene</td><td rowspan=1 colspan=1>MDx-Chex for BCID2Control 1 - GN</td><td rowspan=1 colspan=1>MDx-Chex for BCID2Control 2 - GPY</td></tr><tr><td rowspan=1 colspan=1>mecA/C andMREJ</td><td rowspan=1 colspan=1>Not detected</td><td rowspan=1 colspan=1>Detected</td></tr><tr><td rowspan=1 colspan=1>vanA/B</td><td rowspan=1 colspan=1>Not detected</td><td rowspan=1 colspan=1>Detected</td></tr><tr><td rowspan=1 colspan=1>KPC</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>CTX-M</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>IMP</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>NDM</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>OXA-48-like</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>VIM</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not detected</td></tr><tr><td rowspan=1 colspan=1>mcr-1</td><td rowspan=1 colspan=1>Detected</td><td rowspan=1 colspan=1>Not detected</td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and does support a substantial equivalence decision.